Pharma giant Takeda is set to create roughly 40 new jobs in Dublin, as it announces that it is investing €40 million in the development of a new facility in Grange Gorman.
The standalone high containment production facility is an expansion of its existing Grange castle footprint, and will be dedicated to manufacturing its oncology product NINLAROTM for global markets.
Takeda is Japan's biggest pharmaceutical company and has had an Irish presence since 1997. It went on to chose Dublin as the location of its first active pharmaceutical ingredient facility outside of Japan in 2002.
Paul Keogh, plant director at Takeda Ireland Grange Castle, said:
“We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide.
We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site.
Jobs Minister Mary Mitchell O’Connor noted the massive contribution the pharma sector is making to the Irish economy:
“Takeda’s decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here."
IDA Ireland CEO Martin Shanahan added:
“Ireland is globally recognised as a centre of excellence in life sciences due to the country’s regulatory track record and talent availability.”
